Therapy of chronic viral hepatitis.
Interferon alpha is effective therapy for patients with chronic hepatitis B and hepatitis C. Only 20% to 40% of patients, however, have a sustained benefit from therapy. For the majority of patients with these diseases, alternative forms of therapy are needed. Nucleoside analogues appear to be extremely promising for the treatment of chronic hepatitis B and will undoubtedly play a major role in the management of this disease. For chronic hepatitis C, prolonged therapy with interferon, improved patient selection, and combined therapy with multiple agents such as ribavirin may lead to an improved therapeutic response.
Fried
M W
MW
Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006509:Hepatitis B / Q000628:therapy*; D006526:Hepatitis C / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D007372:Interferons